

## InVivoSIM anti-human amyloid-beta (Solanezumab Biosimilar)

**Attention:** Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

### Lot Specific Information

**Lot Number:** Lot Specific\*  
**Volume:** Lot Specific\*  
**Concentration:** Lot Specific\* (generally 4 to 11 mg/ml) \*  
**Total Protein:** Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

### Product Information

**Catalog Number:** SIM0047  
**Clone:** Solanezumab  
**Isotype:** Human IgG1,  $\kappa$   
**Recommended Isotype Control(s):** RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme  
**Recommended Dilution Buffer:** InVivoPure pH 7.0 Dilution Buffer  
**Immunogen:** Human APP Abeta, soluble monomer  
**Reported Applications:**  
*in vivo* functional assays  
*in vitro* functional assays  
ELISA  
Western blot  
Immunohistochemistry (paraffin)  
**Formulation:** PBS, pH 7.0  
Contains no stabilizers or preservatives  
**Endotoxin:** <0.5EU/mg (<0.0005EU/ $\mu$ g)  
Determined by LAL gel clotting assay  
**Purity:** >95%  
Determined by SDS-PAGE  
**Sterility:** 0.2  $\mu$ m filtration  
**Production:** Purified from cell culture supernatant in an animal-free facility  
**Aggregation:** <5%  
Determined by SEC  
**RRID:**  
**Molecular Weight:** 150 kDa

### Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

### Description

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Solanezumab, making it ideal for research use. Solanezumab is a humanized IgG1 $\kappa$  anti-human APP antibody, and it reacts preferentially with soluble monomers rather than fibrillar beta-amyloid or abeta. Solanezumab does not bind A $\beta$ 's aggregated forms. A $\beta$  is a peptide that is suggested to play a critical role in the pathogenesis of Alzheimer's disease (AD), and this peptide is generated through the aberrant protein processing of amyloid- $\beta$  protein precursor (APP or A $\beta$ PP). APP undergoes its initial cleavage by either  $\alpha$ - or  $\beta$ -Secretase (or BACE1).  $\alpha$ -Secretase mediated cleavage of APP leads to the formation of sAPP $\alpha$

and the  $\alpha$ -C-terminal fragment ( $\alpha$ -CTF or APP-C83).  $\beta$ -Secretase cleaves sAPP $\beta$  and the  $\beta$ -C-terminal fragment ( $\beta$ -CTF or APP-C99).  $\gamma$ -Secretase further cleaves C99 and C83 to P3 and A $\beta$  respectively. A $\beta$ 's amino acid length can range from 37 to 43, depending on the location of  $\gamma$ -secretase cleavage and the two main A $\beta$  species are A $\beta$ 42 and A $\beta$ 40. A $\beta$ 42 is present in amyloid plaques more frequently than A $\beta$ 40, and A $\beta$  drives the basic neuropathological abnormalities in AD that are characterized by the presence of neurofibrillary tangles, i.e., intraneuronal protein clusters, composed of paired helical filaments of the hyperphosphorylated tau protein, a microtubule-associated protein, and extracellular A $\beta$  aggregates (senile plaques). Solanezumab recognizes a conformational epitope in the central region of human A $\beta$  (amino acid residues 16-26), thereby reacting with various N-terminally truncated species of A $\beta$  (e.g., Ab3-42) that are known to exist alongside full-length A $\beta$  (Ab1-42) in AD senile plaques. Preclinical studies involving the in vivo administration of Solanezumab have shown that this antibody promotes A $\beta$  clearance from the brain.

## Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

## Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.


## Application References

For a complete list of references, visit [https://bioxcell.com/sim0047?bxcs=9k1b3a#tab\\_references](https://bioxcell.com/sim0047?bxcs=9k1b3a#tab_references) or scan the QR code below.



## Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail [technicalservice@bioxcell.com](mailto:technicalservice@bioxcell.com).



**Bio X Cell, LLC**  
<https://bioxcell.com>  
+1-866-787-3444  
[customerservice@bioxcell.com](mailto:customerservice@bioxcell.com)

*Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.*

*Not for resale.*

**Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC**